Abstract
Objective: The aim of this study is to compare two different palliative radiotherapy regimes - standard hypofractionated regime and split course hypofractionated regime in advanced head and neck cancer. Methods: 60 untreated patients of advanced squamous cell carcinoma of head and neck who were treated with palliative intent were randomized into two arms: Arm A (n=30) patients received 30 Gy in 10 fractions in two weeks; Arm B (n=30) patients received 1750 cGy in 5 fractions followed by a three weeks gap and then again 1750 cGy in 5 fractons, treatment completed in 5 weeks. Result: The response was comparable in both the arms. Symptom palliation was also similar; pain relief was 76% in both arms and relief of dysphagia 73% in arm A vs 79% in arm B. Partial response rate was equivalent (69% vs 62%). Mucositis and upper GI toxicity did not show any significant difference. Patient drop out was only 1 in arm B compared to 4 in arm A. The BED10 values are 39 and 37.84 in arm A and B respectively; whereas the BED3 values are 60 and 75.8. Conclusion: We conclude that the second regime can also be used in palliative setting in some selected patients. Key words: Advanced head and neck cancer; Palliative Radiation. DOI: 10.3329/bjo.v17i1.7620 Bangladesh J Otorhinolaryngol 2011; 17(1): 29-35
Highlights
Squamous cell carcinoma of head and neck (SCCHN) is one of the commonest cancers seen in India, constituting around 25% of the overall cancer burden
Advanced SCCHN bears a poor prognosis and patients usually die of uncontrolled loco-regional disease
We report our experience with a hypofractionated radiotherapy regimen and a split course radiotherapy regimen for palliation of loco-regionally advanced and incurable SCCHN; both radiobiologically as well as by clinical outcomes
Summary
Squamous cell carcinoma of head and neck (SCCHN) is one of the commonest cancers seen in India, constituting around 25% of the overall cancer burden. It is the commonest cancer among males in India. The vast majority of them present with loco-regionally advanced disease where achievement of cure is difficult. Advanced SCCHN bears a poor prognosis and patients usually die of uncontrolled loco-regional disease. The fiveyear survival of advanced SCCHN even with. Bangladesh J Otorhinolaryngol aggressive treatment is less than 20%, with a median survival of around 12 months. These patients suffer from radiation toxicities that further compromise their quality of life
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.